심부전(HF) 시장 : 질병 관리, 역학, 파이프라인 평가, 미충족 수요, 의약품 예측(-2032년)

Heart Failure in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032

US $ 14,995 ￦ 21,105,000

Zip (Single User License)

ZIP파일 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 29,990 ￦ 42,210,000

Zip (Site License)

ZIP파일 보고서를 동일 기업의 한 부서에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 44,985 ￦ 63,316,000

Zip (Global License)

ZIP파일 보고서를 동일 기업(해외)의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

미국, 프랑스, 독일, 이탈리아, 스페인, 영국, 일본 등 주요 7개 시장(미국, 프랑스, 독일, 이탈리아, 스페인, 영국, 일본)의 심방세동 치료제 매출은 2022년 약 319억 달러에서 2032년 530억 달러에 달하고, 연평균 복합 성장률(CAGR) 5.2%의 높은 성장률을 나타낼 것으로 예상됩니다. 세 가지 first-in-class drugs의 도입이 전체 시장을 가장 강력하게 견인할 것으로 예상됩니다.

급성 HF도 예측 기간 동안 7개 주요 시장 전체에서 성장할 것으로 예상되며, 특히 여러 파이프라인 급성기 약물과 만성 HF 악화 시 사용되는 급성기 이후 치료법 개발이 그 요인으로 작용할 것으로 보입니다.

예측 기간 동안 HF 시장의 주요 성장 촉진요인은 다음과 같습니다.

• 나트륨-포도당 공수송체 억제제의 적응증 확대가 예상됩니다.
• 여러 가지 경구제와 주사제 출시
• 세계 만성 HF 유병률 증가

예측 기간 동안 HF 시장 성장을 저해하는 주요 장벽은 다음과 같습니다.

• 최근 개발된 HF 치료제의 높은 가격
• 심장 전문의 및 기타 의사들이 새로운 HF 치료법을 채택하거나 처방하는 데 소극적
• 제네릭 HF 의약품의 사용 확대는 고가의 브랜드 치료제 시장 침투를 어렵게 하고 있습니다.

7대 주요 시장의 만성 HF 시장 규모는 2022년 296억 달러에서 2032년까지 490억 달러에 달하고, 연평균 복합 성장률(CAGR) 5.2% 성장할 것으로 예상됩니다.

이 보고서는 주요 7개 시장(미국, 프랑스, 독일, 이탈리아, 스페인, 영국, 일본)의 심부전(HF)에 대해 조사 분석했으며, 시장 역학, 지역 및 부문 분석, 기업 프로파일 등의 정보를 제공합니다.

목차

제1장 심부전 : 주요 요약

• HF 시장은 2022년-2032년에 강력한 성장을 나타냅니다
• CV 의약품 라벨 확대가 시장 성장을 가속
• 확립된 치료법을 이용할 수 있는 것에도 불구하고, 시장에 미충족 요구가 남아 있다.
• 경구제가 HF 시장을 독점
• 의사의 견해

제2장 서론

제3장 질환 개요

• 병인과 병태생리학
• 분류 또는 병기 분류 시스템
• 예후

제4장 역학

• 질환 배경
• 위험 요인과 병존 질환
• 세계의 과거 동향
• 예측 방법
• 심부전 역학 예측(2022년-2032년)
• 논의
  • 역학 예측 인사이트
  • COVID-19의 영향
  • 분석의 한계
  • 분석의 강점

제5장 질병 관리

• 진단과 치료 개요
• 질병 관리에 대한 KOL 인사이트

제6장 경쟁 평가

• 개요

제7장 미충족 요구와 기회 평가

• 개요
• HF-PEF 환자에 대한 치료법 결여
• 급성 심부전에 대한 치료법 결여
• HF치료 최적인 관리
• 심부전을 발병하는 리스크 있는 환자에 대한 예방 요법

제8장 연구개발 전략

• 개요
  • 기타 적응증에 대해 승인된 치료법 라벨 확대
  • 제품 파이프라인을 확대하는 합병과 인수
• 임상시험 설계
  • 심부전 임상 엔드포인트
  • 포함 기준과 제외 기준

제9장 파이프라인 평가

• 개요
• 임상 개발 중인 유망한 의약품

제10장 파이프라인 평가 분석

• 개요
• 경쟁 평가

제11장 현재와 향후 기업

• 개요
• Amgen and Cytokinetics
• Bayer
• Zensun
• AstraZeneca
• Boehringer Ingelheim
• Lexicon
• Johnson & Johnson
• Viatris
• CSL Vifor
• Eli Lilly
• Otsuka
• Novartis
• Novo Nordisk
• Mesoblast
• BioCardia
• 거래 성립 동향

제12장 시장 전망

• 세계 시장
• 미국
• 유럽 5개국
• 일본

제13장 부록

LSH

영문 목차

영문목차

Abstract

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the Heart Failure (HF) market through 2032.

GlobalData estimates sales of HF therapeutics to be approximately $31.9 billion across the 7MM in 2022. By 2032, GlobalData expects the HF market to grow at a strong Compound Annual Growth Rate (CAGR) of 5.2%, reaching sales of $53 billion by the end of the forecast period. GlobalData expects uptake of SGLT2 inhibitors and three first-in-class drugs to be the strongest driver of the total HF markets in the 7MM.

Acute HF will also see growth across the 7MM over the forecast period, most notably due to the development of multiple pipeline acute agents and the post-acute therapies, used in cases of worsening chronic HF.

Major drivers of HF market growth over the forecast period are the -

• Anticipated expanded indications for sodium-glucose co-transporter inhibitors.
• Launch of several oral and injectable agents.
• Increase in the global prevalence of chronic HF.

Major barriers that will restrict the growth of the HF market during the forecast period are the -

• High price of recently developed HF therapies.
• General reluctance of cardiologists and other physicians to adopt and prescribe new HF therapies.
• Widespread use of generic HF drugs, making it difficult for high-priced branded therapies to penetrate the market.

The 7MM chronic HF market size in 2022 was $29.6 billion, and is expected to increase to $49 billion by 2032 at a CAGR of 5.2%.

Key Highlights

In 2022, GlobalData estimated that the global HF market reached $31.9 billion across the 7MM, and expects the HF market to grow at a strong Compound Annual Growth Rate of 5.2%, reaching sales of $53 billion by 2032.

Major drivers of HF market growth over the forecast period are the:

Anticipated expanded indications for sodium-glucose co-transporter inhibitors.

Launch of several oral and injectable agents.

Increase in the global prevalence of chronic HF.

Scope

• Overview of HF, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized HF therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2022 to 2032.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the HF therapeutics market.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for HF treatment. The most promising candidates in late-stage development are profiled.
• Analysis of the current and future market competition in the global HF therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the 7MM HF therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM HF therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Table of Contents

1 Heart Failure: Executive Summary

• 1.1 The HF Market Will Exhibit Strong Growth Between 2022 and 2032
• 1.2 Label expansions of CV drugs will fuel market growth.
• 1.3 Unmet needs remain in the HF market despite the availability of well-established therapies.
• 1.4 Oral agents will dominate HF market.
• 1.5 What do physicians think?

2 Introduction

• 2.1 Catalyst
• 2.2 Related reports

3 Disease Overview

• 3.1 Etiology and pathophysiology
  • 3.1.1 Etiology
  • 3.1.2 Pathophysiology
  • 3.1.3 Biomarkers/Targets of interest
• 3.2 Classification or staging systems
• 3.3 Prognosis

4 Epidemiology

• 4.1 Disease background
• 4.2 Risk factors and comorbidities
• 4.3 Global and historical trends
• 4.4 Forecast methodology.
  • 4.4.1 Sources
  • 4.4.2 Forecast assumptions and methods.
  • 4.4.3 Forecast assumptions and methods: diagnosed incident cases of HF - 7MM.
  • 4.4.4 Forecast assumptions and methods: diagnosed incident cases of HF by EF
  • 4.4.5 Forecast assumptions and methods: hospitalizations for acute HF.
  • 4.4.6 Forecast assumptions and methods: acute HF hospitalizations based on presentation.
  • 4.4.7 Forecast assumptions and methods: hospital LoS days for acute HF hospitalizations.
  • 4.4.8 Forecast assumptions and methods: re-admissions within 30 days post-discharge after acute HF hospitalization.
  • 4.4.9 Forecast assumptions and methods: diagnosed prevalent cases of HF - 7MM.
  • 4.4.10 Forecast assumptions and methods: diagnosed prevalent cases of HF by EF
  • 4.4.11 Forecast assumptions and methods: diagnosed prevalent cases of HF by NYAH classes.
  • 4.4.12 Forecast assumptions and methods: diagnosed prevalent cases of HF-PEF (LVEF≥50%) NYHA Class
  • 4.4.13 Forecast assumptions and methods: diagnosed prevalent cases of HF-mrEF (LVEF= 40-49%) NYHA class
  • 4.4.14 Forecast assumptions and methods: diagnosed prevalent cases of HF-REF (LVEF <40%) by NYHA class.
  • 4.4.15 Forecast assumptions and methods: diagnosed prevalent cases of HF by ACCF/AHA stages.
• 4.5 Epidemiological forecast for heart failure (2022-32)
  • 4.5.1 Diagnosed incident cases of HF.
  • 4.5.2 Age-specific diagnosed incident cases of HF
  • 4.5.3 Sex-specific diagnosed incident cases of HF
  • 4.5.4 Diagnosed incident cases of HF by EF
  • 4.5.5 Hospitalizations for acute HF
  • 4.5.6 Acute HF hospitalizations based on presentation.
  • 4.5.7 Hospital LoS for acute HF
  • 4.5.8 Re-admissions within 30 days post-discharge after acute HF
  • 4.5.9 Diagnosed prevalent cases of HF.
  • 4.5.10 Age-specific diagnosed prevalent cases of HF
  • 4.5.11 Sex-specific diagnosed prevalent cases of HF
  • 4.5.12 Diagnosed prevalent cases of HF by EF
  • 4.5.13 Diagnosed prevalent cases of HF by NYHA classes.
  • 4.5.14 Diagnosed prevalent cases of HF-PEF (LVEF ≥50%) by NYHA class.
  • 4.5.15 Diagnosed prevalent cases of HF-mrEF (LVEF = 40-49%) by NYHA class
  • 4.5.16 Diagnosed prevalent cases of HF-REF (LVEF <40%) by NYHA class
  • 4.5.17 Diagnosed prevalent cases of HF by ACCF/AHA stages.
• 4.6 Discussion
  • 4.6.1 Epidemiological forecast insight
  • 4.6.2 COVID-19 impact.
  • 4.6.3 Limitations of the analysis
  • 4.6.4 Strengths of the analysis

5 Disease Management

• 5.1 Diagnosis and treatment overview
• 5.2 KOL insights on disease management

6 Competitive Assessment

• 6.1 Overview

7 Unmet Needs and Opportunity Assessment

• 7.1 Overview
• 7.2 Lack of therapies for HF-PEF patients
• 7.3 Lack of therapies for acute HF
• 7.4 Optimal management of HF treatments
• 7.5 Preventative therapies for patients at risk of developing HF.

8 R&D Strategies

• 8.1 Overview
  • 8.1.1 Label expansion for therapies approved for other indications.
  • 8.1.2 Mergers and acquisitions to expand product pipeline.
• 8.2 Clinical Trials Design
  • 8.2.1 Clinical endpoints for HF
  • 8.2.2 Inclusion and exclusion criteria

9 Pipeline Assessment

• 9.1 Overview
• 9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

• 10.1 Overview
• 10.2 Competitive assessment

11 Current and Future Players

• 11.1 Overview
• 11.2 Amgen and Cytokinetics
• 11.3 Bayer
• 11.4 Zensun
• 11.5 AstraZeneca
• 11.6 Boehringer Ingelheim
• 11.7 Lexicon
• 11.8 Johnson & Johnson
• 11.9 Viatris
• 11.10 CSL Vifor
• 11.11 Eli Lilly
• 11.12 Otsuka
• 11.13 Novartis
• 11.14 Novo Nordisk
• 11.15 Mesoblast
• 11.16 BioCardia
• 11.17 Deal-making trends

12 Market Outlook

• 12.1 Global markets
• 12.2 US
• 12.3 5EU
• 12.4 Japan

13 Appendix

• 13.1 Bibliography
• 13.2 Abbreviations
• 13.3 Methodology
  • 13.3.1 Forecasting methodology
• 13.4 Primary research - KOLs interviewed for this report.
  • 13.4.1 KOLs
• 13.5 Primary research - prescriber survey
• 13.6 About the authors
  • 13.6.1 Analyst
  • 13.6.2 Therapy Area Director
  • 13.6.3 Epidemiologist
  • 13.6.4 Vice President of Disease Intelligence and Epidemiology
• Contact Us

관련자료